aap Implantate AG

Regulatory Filings • Jun 15, 2017

News Details

Ad-hoc | 15 June 2017 10:54

aap Implantate AG: Public Share Buyback Offer

aap Implantate AG / Key word(s): Share Buyback/Corporate Action

15-Jun-2017 / 10:54 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

---

The Management Board of aap Implantate AG resolved on 15 June 2017 with the approval of the Supervisory Board of the same day to purchase up to 2.25 million no-par value bearer shares of the company by means of a voluntary public share buyback offer against a cash payment of EUR 1.52 per no-par value share for a maximum total purchase price (including incidental costs) of up to EUR 3.5 million. The shares offered for purchase correspond to a proportion of up to approximately 7.3% of the company’s current share capital. With the public share buyback offer the Management Board makes use of the authorization granted by the Annual General Meeting resolution of 13 June 2014 to acquire treasury shares. With this measure aap Implantate AG implements the announced partial distribution of proceeds from last year’s sale of the subsidiary aap Biomaterials GmbH to shareholders.

The shares which are acquired as a result of the public share buyback offer can be used for all purposes permitted by law. The Management Board intends to redeem the shares acquired by means of the public share buyback offer.

The acceptance period starts on Tuesday, 20 June 2017, 00.00 hours (CEST) and ends on Monday, 10 July 2017, 24.00 hours (CEST). The offer document will be published before the start of the acceptance period on the corporate website of the company (www.aap.de) in the section “Investors / Share Buyback” as well as in the Federal Gazette under www.bundesanzeiger.de.

_______________________________________________________________________________________

aap Implantate AG (ISIN DE0005066609) – Prime Standard/Regulated Market – All German stock markets –

About aap Implantate AG

aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven’t yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG’s stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company’s investor relations app from the Apple’s App Store or Google Play.

Forward-looking statement

This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap ‘s public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

Contact:

aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 – 134; Fax.: ++49/30/750 19 – 290; f.franke@aap.de

---

15-Jun-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.dgap.de

---

Language:	English
Company:	aap Implantate AG
	Lorenzweg 5
	12099 Berlin
	Germany
Phone:	+49 (0) 30 75 01 90
Fax:	+49 (0) 30 75 01 91 11
E-mail:	info@aap.de
Internet:	www.aap.de
ISIN:	DE0005066609
WKN:	506660
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

End of Announcement	DGAP News Service